Therapy Areas: Central Nervous System
Sanofi to produce Principia Biopharma's Bruton's tyrosine kinase PRN2246
13 November 2017 -

Sanofi, a France-based multinational pharmaceutical company, has agreed to produce Principia Biopharma's Bruton's tyrosine kinase inhibitor, PRN2246, it was reported on Friday.

The product is intended for the treatment of multiple sclerosis and possibly other central nervous system diseases.

The contract between the firms provides Sanofi with an exclusive, worldwide license to develop and commercialise PRN2246, which is presently in clinical development. According to the agreement, Principia will receive USD40m upfront payment, future milestone payments that are likely to cost USD765m and royalties on product sales.

The experimental oral treatment, PRN2246, has been designed to gain access to the brain and spinal cord by overcoming the blood-brain barrier and affecting immune cell and brain cell signalling. As per the deal, Principia has been given an option to co-fund phase three development of the product. This would be in exchange for increased royalties on global product sales or a profit and loss sharing arrangement in the US. According to the partners, the license transaction is likely to be completed in the fourth quarter of 2017, if it can clear customary regulatory approvals.

Login
Username:

Password: